Morinaga Milk's B. longum BB536 Probiotic May Prevent Intestinal Disorders Induced by Animal-Based Diet
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading dairy product company in Japan, today unveiled new research showing that daily consumption of yogurt fortified with the company’s proprietary probiotic Bifidobacterium longum BB536 prevents the intestinal bacterial imbalance induced by an animal-based diet. BB536 maintained healthy levels of beneficial bacteria, while preventing increases of harmful levels of bacteria such as Bilophila.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160211005072/en/
Recently, studies have demonstrated the importance of maintaining balanced intestinal flora to overall health. However, the modern, fast-paced lifestyle — with its lack of sleep and exercise, irregular dietary habits and continual stress — threatens bacterial balance. Eating an animal-based diet in particular has been shown to cause an increase in harmful bacteria, a condition known as dysbiosis. This problem is not confined to the United States. Due to Westernization, animal-based diets are growing in popularity in countries across the world.
The effect of animal products on bacterial balance is strong and immediate. In fact, a 2014 study published in the scientific journal Nature showed that consumption of an animal-based diet composed entirely of meat and eggs for just one day caused negative changes in the composition and function of intestinal flora, including dysbiosis.1 However, consumption of BB536-fortified yogurt prevented these harmful changes, as shown in Morinaga’s new research.
“Consumption of BB536-fortified yogurt prevented the GI deterioration caused by an animal-based diet, which indicates it may be able to prevent various intestinal disorders caused by eating a poor diet — just by adding one BB536 yogurt to the daily diet per day,” Dr. Jin-zhong Xiao, General Manager of Morinaga’s Next Generation Science Institute, explained.
“Importantly, probiotics are not interchangeable.” Dr. Xiao points out that “Probiotics are all strain-specific, as each strain has different indications and characteristics. Bifidobacterium longum is one of the predominant bacteria in the human intestine, and it is clinically confirmed that yogurt containing BB536 is more efficacious for eliminating harmful substances and modulating intestinal microflora compared to conventional yogurt.”
In the study, 31 healthy adults were randomly classified into 3 groups (A, B and C). After an observation period of 7 days, the subjects consumed an animal-based diet consisting entirely of meat and eggs for 5 days (the animal-based diet period) followed by a balanced diet (the recovery period) for 14 days. Group A consumed no BB536 yogurt during the whole study period, while group B consumed 100g of BB536 yogurt twice a day during the recovery period only, and group C consumed 100g of BB536 yogurt twice a day during both the animal-based diet period and the recovery period. Throughout the study, fecal samples were collected, and intestinal bacterial flora was analyzed before and after the animal-based diet period and after the recovery period (Fig. 1).
BB536 Yogurt Prevents Decrease in Beneficial Bifidobacteria (Fig.2 Left)
Bifidobacteria counts in the feces decreased significantly during the animal-based diet period in both groups A and B. However, this decrease was not observed in subjects in group C, who consumed BB536 yogurt together with the animal-based diet. Moreover, the Bifidobacteria tended to decrease further during the recovery period in group A, which ate no BB536 yogurt, while it tended to increase in group B, getting close to the original condition before starting the animal-based diet. These findings demonstrate the potential of Bifidobacterium longum BB536 not only to prevent diet-related gut flora disorders, but also to aid in their recovery.
BB536 Yogurt Also Prevents Increase in Harmful Bilophila (Fig.2 Right)
Consistent with the results of the above-mentioned Nature study, the present study found that an animal-based diet increased a genus of harmful bacteria called Bilophila. Bilophila is thought to induce inflammation in the intestines by producing the harmful substance hydrogen sulfide, which damages the intestinal mucous membrane2 and has been reported to be elevated in patients with appendicitis.3 However, no significant increase of this harmful bacterial genus was observed in group C subjects. B. longum BB536 showed superior results in regulating intestinal function, had a protective effect against the enteropathogenic Escherichia coli O-1574 and helped eradicate the enterotoxigenic Bacteroides fragilis (ETBF), which is associated with the development of colorectal cancer.5
About Bifidobacterium longum BB536
BB536 is one of the strains of Human Residential Bifidobacteria, which naturally reside in human intestines and are natural parts of human digestive systems. It is one of the most thoroughly researched probiotic strains in the world. Morinaga has conducted research and development on BB536 for over 40 years and achieved GRAS status in the U.S. in 2009. Supported by over 120 published studies, BB536’s beneficial effects have been confirmed in such clinical areas as intestinal health, immunity, infection, and allergy.
Morinaga Milk Industry Co., Ltd. is one of the major dairy product companies in Japan. Founded in 1917 and employing over 3,000 people, Morinaga excels in innovative technology and offers dairy products and other beneficial functional ingredients to customers around the world. For more information, visit us at http://www.morinagamilk.co.jp/english/.
1. Nature 505, 559-563(2014)
2. Nature 487, 104-108(2012)
3. PLoS One 4, e95414(2014)
4. Bios. Microflora 22, 85-91(2003)
5. Anaerobe 18, 14-18(2012)
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Announcement by Viking Corp on Tecnotree22.6.2018 11:09 | Pressemelding
In the interests of stakeholder transparency, this announcement provides background and context to Viking's file bankruptcy proceedings upon Tecnotree: As many of you will now know, Viking Corp was recently forced to file bankruptcy proceedings upon Tecnotree, which were withdrawn on the 19 June. In the interests of stakeholder transparency, we make this Announcement to provide background and context to this action. Firstly, we would reflect on the recent history of our attempts to partner with Tecnotree and all its stakeholders. Viking launched a Tender Offer (TO), having conducted detailed discussions with the Tecnotree Board and our advisors. On the basis of those discussions, we were very confident that the TO price of 10 cents per share provided truly superior value for shareholders. So did the Tecnotree Board as evidenced by their unanimous recommendation of our Offer and of course, further evidenced by the current prevailing market price. This TO was supported in the most vigoro
HeartSciences Named “Start-Up to Watch”22.6.2018 11:00 | Pressemelding
HeartSciences is delighted to have been highlighted as “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist. The article titled “HEARTSCIENCES: ARTIFICIAL INTELLIGENCE IMPROVES FRONTLINE RISK STRATIFICATION FOR HEART DISEASES” discusses HeartSciences’ role in addressing the current challenges and significant unmet need to identify heart disease at an early stage and reduce the high prevalence of expensive diagnostic testing with low yields. The article highlights the enormous opportunity for HeartSciences’ breakthrough MyoVista® Wavelet ECG (wavECG™) technology to benefit patients and to reduce health system costs and references a recently published study titled “Prediction of Abnormal Myocardial Relaxation From Signal Processed Surface ECG” in the Journal of American College of Cardiology (JACC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005088/en/ MyoVista Wavelet ECG Cardiac Testing Device (P